No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Huakang Biomed (08622): Xu Ming has been appointed as a non-executive director.
huakang biomed (08622) announced that Xu Ming has been appointed as a non-executive director of the company, effective from October 2024...
HUAKANG BIOMED: 2024 INTERIM REPORT
Huakang Biomed (08622) announced its interim results, with a net loss of approximately 1.779 million yuan attributable to owners, a 22.27% year-on-year increase in the loss.
Huakang Biomed (08622) announced its 2024 interim performance, with revenue increasing by about 4% YoY to 11.9 million yuan...
HUAKANG BIOMED: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
Huakang Biomedical Holdings Vice Chairman Yim Yang Chang Sells 31% Of Holding
No Data
